Please select the therapeutic area you would like to see more about.
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Bamlanivimab has not been approved, but has been authorized for emergency use by FDA, to treat mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization*.* Bamlanivimab is an investigational drug that has not been approved by the FDA for any use. It is not yet known if bamlanivimab is safe and effective for the treatment of COVID-19. This use is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use, unless the authorization is terminated or revoked sooner.
If you have immediate questions regarding COVID-19, or to report an Adverse Event or Product Complaint, please call us.